Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • Health Equity through Her Lens
    • The Health Equity podcast
    • Access insights
    • Health Equity through Her Lens
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

RI New York 2019: SDGs and impact investing

On Wednesday 4 December 2019, Bowen Gu, Investor Engagement Manager at the Access to Medicine Foundation will join a panel discussion at RI New York on the SDGs and impact investing.

Date

04 December 2019

The panel will look at how the SDGs are creating change and value through the business and institutional investment chain, what the investment benchmarking of companies against SDG progress looks like, why do it, as well as how asset owners and society at large interpret successful SDG investment.

Bowen will discuss the latest and upcoming research at the Access to Medicine Foundation, and how investors have been using the Access to Medicine Index and Antimicrobial Resistance (AMR) Benchmark, in their impact investing strategies, as well as engagement and stewardship activities.

Speakers:

  • Bowen Gu, Investor Engagement Manager, Access to Medicine Foundation

  • Namtse Namgyal, Head of Institutional Sales, North America, Trucost, part of S&P Global 

  • John Levy, Director of Impact, FT Real Asset Advisors, Franklin Templeton

There is increasing recognition that access to medicine is material for the pharmaceutical industry. More than 95 investors - together managing assets of more than USD 13 trillion - have signed the Access to Medicine Index Investor Statement and committed to using the Index in their investment analysis and engagements with companies. Find out more about our work with investors here.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved